Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Olumiant
Synonyms :
baricitinib
Class :
Antirheumatics, DMARDS, and JAK inhibitors
Brand Name :
Olumiant
Synonyms :
baricitinib
Class :
Antirheumatics, DMARDS, and JAK inhibitors
Dosage Forms and StrengthsÂ
TabletsÂ
1mgÂ
2mgÂ
4mgÂ
2
mg
Tablets
Orally 
once a day
It is not advised to use this medication in conjunction with biologic DMARDs, other Janus kinase (JAK) inhibitors, or potent immunosuppressants (such as cyclosporine or azathioprine)
This medication can be taken either alone or in conjunction with other nonbiologic DMARDs, such as methotrexate
Indication: For the management of individuals with moderate to serious active rheumatoid arthritis who did not respond well to at least one TNF inhibitor
4
mg
Tablets
Orally 
once a day
2
weeks
Indication: Recommended for the management of adults hospitalized with suspected or laboratory-confirmed COVID-19 (coronavirus disease 2019) who need extracorporeal membrane oxygenation (ECMO), invasive or non-invasive mechanical ventilation, or supplemental oxygen
2
mg
Tablets
Orally 
once a day
The dose may be increased to 4mg if there is no response
It is not advised to use this medication in conjunction with cyclosporine, biologic immunomodulators, other potent immunosuppressants, or other JAK inhibitors
Indication: used to treat alopecia areata
For individuals experiencing significant eyelash or eyebrow hair loss, whether or not they have lost all of their scalp hair, it is recommended to take 4 mg once daily
Dosage Forms and StrengthsÂ
TabletsÂ
1mgÂ
2mgÂ
4mgÂ
For investigational use only
For children from 2 years to 9 years:
Tablets
Orally 
once a day
2
weeks
For children aged 9 and older
4mg orally, one time a day for two weeks
Refer to adult dosingÂ
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
the immunosuppressive effect of either of the drugs is raised, leading to increased chances of infection
it may reduce the therapeutic effect of covid-19 vaccines 
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may diminish the excretion rate of amantadine
immunosuppressants increase the effect of baricitinib
immunosuppressants increase the effect of baricitinib
immunosuppressants increase the effect of baricitinib
immunosuppressants increase the effect of baricitinib
immunosuppressants increase the effect of baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
baricitinib exerts an antagonistic pharmacodynamic effect on the live rotavirus oral vaccine, leading to a reduction in its efficacy
baricitinib's effect can be enhanced by the concurrent administration of probenecid, as it reduces the elimination process
the toxicity of either of the drugs is increased by immunosuppressive activity
the efficacy of BCG vaccine live is reduced by baricitinib due to immunosuppression
the toxicity of either of the drugs is increased by immunosuppressive activity
the effect of either of the drugs is increased due to immunosuppression
the toxicity of either of the drugs is increased by immunosuppressive activity
the toxicity of either of the drugs is increased by immunosuppressive activity
the toxicity of either of the drugs is increased by immunosuppressive activity
the toxicity of either of the drugs is increased by immunosuppressive activity
the effect of baricitinb is increased by irbesartan
the effect of baricitinb is increased by ketorolac
the effect of baricitinb is increased by nateglinide
the effect of baricitinb is increased by pioglitazone
the toxicity of either of the drugs is increased by immunosuppressive activity
the toxicity of either of the drugs is increased by immunosuppressive activity
May increase the immunosuppressive effect of barcitinib
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, the metabolism of baricitinib increases   
may enhance the immunosuppressive effect of immunosuppressants
When both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of severe and potentially fatal infection   
when both drugs are combined, there may be an increased risk of severe and potentially fatal infections  
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
combination should be avoided, may enhance the toxicity of the other by immunosuppressive effects
when both drugs are combined, there may be an increased risk or severity of adverse effects  
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
when both drugs are combined, there may be an increased risk and severity of life-threatening infections  
When both drugs are combined, there may be an increased risk of severe and potentially fatal infections  
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
it enhances the immunosuppressant activity of baricitinib
may enhance the immunosuppressive effect of immunosuppressants
it may increase the immunosuppressive effect of baricitinib 
may increase the immunosuppressive effects
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may increase the immunosuppressive effects
may decrease the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressive agents
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
antithymocyte globulin equineÂ
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may enhance the immunosuppressive effect of baricitinib
may enhance the immunosuppressive effect of baricitinib
may enhance the immunosuppressive effect of baricitinib
may enhance the immunosuppressive effect of baricitinib
may enhance the immunosuppressive effect of baricitinib
it may diminish the excretion rate when combined with corifollitropin alfa resulting in an enhanced serum level
When baricitinib is used together with fluconazole, this leads to reduction in the baricitinib metabolism
tinidazole has the potential to reduce the rate of excretion of baricitinib, potentially leading to an elevation in level of serum
When mometasone furoate is used together with baricitinib, this leads to enhanced risk or seriousness of adverse outcomes
cefpirome leads to a reduction in the rate of excretion of baricitinib which leads to increased level of serum
baricitinib leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
baricitinib leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
the excretion rate of baricitinib may be decreased by gadopentetic acid, leading to a higher serum level
baricitinib: it may decrease the excretion rate of iothalamic acid
baricitinib: it may decrease the excretion rate of abacavir CNS depressant
baricitinib: it may decrease the excretion rate of abacavir CNS depressant
baricitinib: it may decrease the excretion rate of abacavir CNS depressant
baricitinib: it may decrease the excretion rate of abacavir CNS depressant
baricitinib: it may decrease the excretion rate of abacavir CNS depressant
baricitinib: it may increase the risk or severity of CNS depression
baricitinib: it may increase the risk or severity of CNS depression
baricitinib: it may increase the risk or severity of CNS depression
when combined with danoprevir, the metabolism of baricitinib can be diminished
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib may decrease the excretion rate of almasilate, leading to higher serum levels
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
may enhance the risk of serious infection by increasing the immunosuppressive effect of methotrexate
may enhance the risk of serious infection by increasing the immunosuppressive effect, avoid combination
may increase excessive immunosuppressive effects
may decrease the therapeutic effect of COVID-19 vaccine
choline magnesium trisalicylate
It may enhance the risk of adverse reactions when combined with Salicylates
the excretory rate of baricitinib may be reduced when taken with mofebutazone that, which results in increased serum levels of baricitinib
the rate of excretion of aurothioglucose may be reduced with baricitinib
the rate of excretion of inositol may be reduced
the risk of adverse effects may be increased
when both drugs are combined, there may be a decrease in the therapeutic effect
the rate of excretion of phosphoric acid may be decreased
the risk of adverse effects may be raised when fluocortolone is taken with baricitinib
Actions and spectrum:Â
Baricitinib is a reversible, selective inhibitor of JAK1 and JAK2, with less affinity for JAK3 and TYK2. Baricitinib alters the signaling pathways of several interferons, interleukins, and growth factors, in addition to inhibiting the activity of JAK proteins. It has also been demonstrated to cause cell apoptosis and reduce the growth of JAK1/JAK2 expression in cells that are mutated.Â
Frequency definedÂ
RAÂ
Infections of the upper respiratory tract (16.3%)Â
Herpes zoster infection (1–1.4%)Â
Elevation in platelets (1-2%)Â
Nausea (2.7-2.8%)Â
Herpes simplex infection (0.8–1.4%)Â
Increased ALT/AST (1.3–4.7%)Â
Neutropenia (0.3%)Â
Acne (1%)Â
Covid-19Â
AST ≥ 3 x ULN (11.8%)Â
ALT ≥ 3 x ULN (18.1%)Â
Neutropenia (2.2%)Â
Infection of the urinary tract (1.5%)Â
Deep vein thrombosis (1.5%)Â
Thrombocytosis (7.9%)Â
Pulmonary embolism (1.5%)Â
Black Box Warning Â
Chances of developing severe or fatal infections may be increasedÂ
Contraindication/Caution:Â
Contraindication:Â
None Â
Pregnancy consideration:Â Â
USFDA pregnancy category: Not assignedÂ
Lactation:Â Â
The excretion of baricitinib into breast milk is unknown.Â
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Pharmacodynamics:Â
An effective treatment for rheumatoid arthritis that also slows down the disease’s progression is baricitinib, a disease-modifying antirheumatic medication (DMARD). Baricitinib was demonstrated to have potent anti-inflammatory effects in laboratory models of inflammatory arthritis. Still, it also preserved bone and cartilage without impairing humoral immunity or having undesirable hematologic effects. In rheumatoid arthritis patients, baricitinib reduced serum C-reactive protein and immunoglobulin levels.Â
Pharmacokinetics:Â Â
AbsorptionÂ
80% of baricitinib is bioavailableÂ
DistributionÂ
50% of baricitinib is bound to plasma proteins and 45% to the serum proteinsÂ
Volume of distribution- 76LÂ
MetabolismÂ
Undergoes metabolism in the liverÂ
Elimination and excretionÂ
75% of baricitinib is excreted through urine, out of which 69% is the unchanged formÂ
20% of the drug is eliminated through feces, out of which 15% is the unchanged drug Â
Half-life:Â
12 hour
Administration:Â
Administered orally with or without mealsÂ
Patient information leafletÂ
Generic Name: baricitinibÂ
Why do we use baricitinib?Â
To treat adult patients with moderate to serious active rheumatoid arthritis who don’t respond well to one or more TNF blockers, baricitinib is indicated. Baricitinib can be taken either as a monotherapy or in conjunction with other DMARDs or methotrexate 9,11.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
